MediWound Ltd. (NASDAQ:MDWD) Poised For Near-Term Repricing As Clinical And Manufacturing Catalysts Arrive
![]() |
MediWound heads into the coming weeks with a catalyst cadence — advancing EscharEx trials while scaling NexoBrid manufacturing — that could force a near-term market revaluation. Operational cash and program milestones shape the immediate risk/reward profile. |









